These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 16123484)

  • 1. The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: a prospective randomized pharmacodynamic study.
    Heise T; Bott S; Tusek C; Stephan JA; Kawabata T; Finco-Kent D; Liu C; Krasner A
    Diabetes Care; 2005 Sep; 28(9):2161-9. PubMed ID: 16123484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial.
    Quattrin T; Bélanger A; Bohannon NJ; Schwartz SL;
    Diabetes Care; 2004 Nov; 27(11):2622-7. PubMed ID: 15504996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microneedle-based intradermal versus subcutaneous administration of regular human insulin or insulin lispro: pharmacokinetics and postprandial glycemic excursions in patients with type 1 diabetes.
    Pettis RJ; Hirsch L; Kapitza C; Nosek L; Hövelmann U; Kurth HJ; Sutter DE; Harvey NG; Heinemann L
    Diabetes Technol Ther; 2011 Apr; 13(4):443-50. PubMed ID: 21355716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique.
    Cernea S; Kidron M; Wohlgelernter J; Modi P; Raz I
    Clin Ther; 2004 Dec; 26(12):2084-91. PubMed ID: 15823772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study.
    Cernea S; Kidron M; Wohlgelernter J; Raz I
    Clin Ther; 2005 Oct; 27(10):1562-70. PubMed ID: 16330292
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro.
    Rave KM; Nosek L; de la Peña A; Seger M; Ernest CS; Heinemann L; Batycky RP; Muchmore DB
    Diabetes Care; 2005 Oct; 28(10):2400-5. PubMed ID: 16186270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time-action profile and patient assessment of inhaled insulin via the Exubera device in comparison with subcutaneously injected insulin aspart via the FlexPen device.
    Forst T; Hohberg C; Schöndorf T; Borchert M; Forst S; Roth W; Dehos B; Pfützner A
    Diabetes Technol Ther; 2009 Feb; 11(2):87-92. PubMed ID: 19848574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan.
    Hirao K; Maeda H; Urata S; Takisawa Y; Hirao S; Sasako T; Sasaki T
    Clin Ther; 2007 May; 29(5):927-934. PubMed ID: 17697911
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Absorption and metabolic effect of inhaled insulin: intrapatient variability after inhalation via the Aerodose insulin inhaler in patients with type 2 diabetes.
    Perera AD; Kapitza C; Nosek L; Fishman RS; Shapiro DA; Heise T; Heinemann L
    Diabetes Care; 2002 Dec; 25(12):2276-81. PubMed ID: 12453973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin.
    Rave K; Bott S; Heinemann L; Sha S; Becker RH; Willavize SA; Heise T
    Diabetes Care; 2005 May; 28(5):1077-82. PubMed ID: 15855570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.
    Plank J; Bodenlenz M; Sinner F; Magnes C; Görzer E; Regittnig W; Endahl LA; Draeger E; Zdravkovic M; Pieber TR
    Diabetes Care; 2005 May; 28(5):1107-12. PubMed ID: 15855574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes.
    Garg S; Rosenstock J; Silverman BL; Sun B; Konkoy CS; de la Peña A; Muchmore DB
    Diabetologia; 2006 May; 49(5):891-9. PubMed ID: 16506054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-response relation of liquid aerosol inhaled insulin in type I diabetic patients.
    Brunner GA; Balent B; Ellmerer M; Schaupp L; Siebenhofer A; Jendle JH; Okikawa J; Pieber TR
    Diabetologia; 2001 Mar; 44(3):305-8. PubMed ID: 11317660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal provision of daytime NPH insulin in patients using the insulin analog lispro.
    Ahmed AB; Home PD
    Diabetes Care; 1998 Oct; 21(10):1707-13. PubMed ID: 9773735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps.
    Levetan C; Want LL; Weyer C; Strobel SA; Crean J; Wang Y; Maggs DG; Kolterman OG; Chandran M; Mudaliar SR; Henry RR
    Diabetes Care; 2003 Jan; 26(1):1-8. PubMed ID: 12502651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. U-100, pH-Neutral formulation of VIAject(®) : faster onset of action than insulin lispro in patients with type 1 diabetes.
    Heinemann L; Nosek L; Flacke F; Albus K; Krasner A; Pichotta P; Heise T; Steiner S
    Diabetes Obes Metab; 2012 Mar; 14(3):222-7. PubMed ID: 21981286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion.
    Raz I; Weiss R; Yegorchikov Y; Bitton G; Nagar R; Pesach B
    Clin Ther; 2009 May; 31(5):980-7. PubMed ID: 19539098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
    Weyer C; Gottlieb A; Kim DD; Lutz K; Schwartz S; Gutierrez M; Wang Y; Ruggles JA; Kolterman OG; Maggs DG
    Diabetes Care; 2003 Nov; 26(11):3074-9. PubMed ID: 14578242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial.
    Hollander PA; Blonde L; Rowe R; Mehta AE; Milburn JL; Hershon KS; Chiasson JL; Levin SR
    Diabetes Care; 2004 Oct; 27(10):2356-62. PubMed ID: 15451900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes.
    Hermansen K; Rönnemaa T; Petersen AH; Bellaire S; Adamson U
    Diabetes Care; 2004 Jan; 27(1):162-7. PubMed ID: 14693983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.